Key Takeaways
- AI scribe use among Australian doctors nearly doubled from 22% (Aug 2024) to 40% (Nov 2025), reflecting rapid adoption to reduce administrative load.
- The federal health department warns that AI scribes operate with “little oversight,” pose data‑security risks when cloud platforms send data overseas, and may affect Medicare costs through claimed revenue boosts.
- Current regulation is fragmented: the Therapeutic Goods Administration (TGA) classifies a scribe as a medical device only if it serves a therapeutic purpose, leaving many tools in a regulatory grey area.
- Inconsistent patient‑consent practices raise concerns about informed consent; clinicians must explain both benefits and limitations of the technology.
- While AI scribes can improve productivity and potentially reduce burnout, their accuracy and reliability remain subject to the limitations of large language models, impacting patient safety and data integrity.
- Ongoing reviews by the TGA, the Office of the Australian Information Commissioner, and Ahpra aim to clarify oversight, but stakeholders question whether existing safeguards are sufficient and consistently applied.
Federal Health Department Raises Oversight Concerns
The Australian federal health department has expressed growing unease about the expanding use of AI scribe technology in clinical settings. In February 2026 Senate estimates briefing documents—released to Guardian Australia under freedom‑of‑information laws—the department noted that AI scribes “have little oversight” and warned of potential risks to patient data security and clinical accountability. The concerns come as the tools, which record, transcribe, and summarise doctor‑patient conversations for medical notes, have surged in popularity over the past 18 months.
Rapid Growth in Adoption Statistics
According to an online poll conducted by the Royal Australian College of General Practitioners (RACGP), the proportion of doctors using AI scribes rose sharply from 22 % in August 2024 to 40 % by November 2025—a near‑doubling in just over a year. Vendors of the technology claim it has been employed hundreds of millions of times worldwide during the same period, driven by clinicians’ desire to alleviate the administrative burden that often contributes to burnout.
Regulatory Ambiguity and Device Classification
Digital scribes are presently treated as medical devices only when they serve a therapeutic purpose under the Therapeutic Goods Act. Many suppliers market their products as falling outside this regulatory scope, describing them as privacy‑compliant tools rather than regulated devices. The health department warned that such positioning may leave users unaware that their cloud‑based platforms could transmit patient data outside Australia, creating significant security and compliance gaps.
Financial Incentives and Medicare Implications
Some scribe providers advertise that their tools can increase a health professional’s revenue by roughly 30 % without requiring additional hours or patient encounters. The department highlighted that such claims have direct implications for the Medicare Benefits Scheme, potentially inflating costs if time saved is redirected toward more billable activity rather than improved patient care or access.
Productivity Gains Versus Accuracy Limits
An April briefing from the department’s AI advisory group acknowledged that AI scribes can boost clinician productivity and may help mitigate burnout. However, the same document cautioned that the technology inherits the quality and accuracy limitations inherent to large language models. These shortcomings could affect patient safety, undermine clinical accountability, and compromise the integrity of data stored in national digital health infrastructures.
Informed Consent Practices Under Scrutiny
The department observed considerable variation in how clinicians and practices obtain patient consent for AI scribe use. It stressed that genuine informed consent requires patients to understand both the benefits and the limitations of the technology they are agreeing to. Reports from patients—including a Melbourne psychiatrist who refused to treat those unwilling to consent—suggest that some clinicians may be pressuring patients to accept the tools, raising ethical concerns about autonomy and transparency.
Fragmented Oversight Across Multiple Agencies
Responsibility for monitoring AI scribes is split among several regulators: the Therapeutic Goods Administration (TGA), the Australian Health Practitioner Regulation Agency (Ahpra), and the Office of the Australian Information Commissioner (OAIC). The TGA is currently reviewing whether digital scribes should be uniformly classified as medical devices, with a report expected in the coming months. Meanwhile, the OAIC has been tracking the rollout closely, meeting with RACGP ethics committees and scribe vendors to address deficiencies in consent protocols and privacy‑policy disclosures.
Privacy Commissioner’s Perspective and Calls for Stronger Safeguards
Privacy Commissioner Carly Kind noted in a May speech that her office has been “tracking closely” the deployment of AI scribe technology. She highlighted ongoing engagement with civil society organisations worried about inadequate consent processes, the lack of transparency in privacy policies, and the potential for data to leave Australian jurisdiction. Kind, alongside consumer advocates like Dr. Elizabeth Deveny of the Consumer Health Forum, urged that existing safeguards be evaluated for strength and consistency, questioning whether time saved by scribes truly translates into better care or merely increased billable activity.
Looking Ahead: Need for Clear, National Standards
As AI scribe adoption continues to accelerate, stakeholders agree that clearer, nationally consistent standards are essential. Such standards should address device classification, data‑security safeguards, mandatory informed‑consent procedures, and mechanisms to monitor any impact on Medicare expenditures and clinician burnout. Only with robust oversight can the potential benefits of AI scribes be realised without compromising patient safety, privacy, or the integrity of Australia’s health system.